Negative inotropic effect of a CB2 agonist A-955840 in isolated rabbit ventricular myocytes is independent of CB1 and CB2 receptors

Current Drug Safety

Volumn 6, Issue 5, 2011, Pages 277-284

  Su, Zhi ^a   Preusser, Lee ^a   Diaz, Gilbert ^a   Green, Jonathon ^a   Liu, Xiaoqin ^a   Polakowski, James ^a   Dart, Michael ^a   Yao, Betty ^a   Meyer, Michael ^a   Limberis, James T ^a   Martin, Ruth L ^a   Cox, Bryan F ^a   Gintant, Gary A ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Cannabinoid receptors; Cardiac myocytes; Dog; Inotropy; L type Ca 2+ current; Rabbit; Sarcomere length

Indexed keywords

A 955840; CALCIUM CHANNEL L TYPE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; RIMONABANT; UNCLASSIFIED DRUG;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CURRENT; CONTROLLED STUDY; DOG; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; IN VITRO STUDY; INOTROPISM; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SARCOMERE; VOLTAGE CLAMP;

ANIMALS; BENZAMIDES; CALCIUM CHANNELS, L-TYPE; DOGS; HEART VENTRICLES; INHIBITORY CONCENTRATION 50; MALE; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; PIPERIDINES; PYRAZOLES; RABBITS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SARCOMERES; THIAZOLES;

EID: 84862949884     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488611798918728     Document Type: Article

References (21)

1. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58: 389-462.
2. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 2008; 7: 438-55.
3. Hiley CR. Endocannabinoids and the heart. J Cardiovasc Pharmacol 2009; 53: 267-76.
4. Bonz A, Laser M, Kullmer S, Kniesch S, Babin-Ebell J, Popp V, et al. Cannabinoids acting on CB1 receptors decrease contractile performacne in human atrial muscle. J Cardiovasc Pharmacol 2003; 41: 657-64.
5. Sterin-Borda L, Del Zar CF, Borda E. Differential CB1 and CB2 cannabinoid receptor-inotropic response of rat isolated atria: Endogenous signal transduction pathways. Biochem Pharmacol 2005; 69: 1705-13.
6. Maslov LN, Lasukova OV, Krylatov AV, Uzhachenko RV, Pertwee R. Selective cannabinoid receptor agonist HU-210 decreases pump function of isolated perfused heart: role of cAMP and cGMP. Bull Exp Biol Med 2004; 138: 550-3.
7. Krylatov AV, Maslov LN, Lasukova OV, Pertwee RG. Cannabinoid receptor antagonists SR141716 and SR144528 exhibit properties of partial agonist in experiments on isolated perfused rat heart. Bull Exp Biol Med 2005; 139: 558-61.
8. Pacher P, Batkai S, Osei-Hyiaman D, et al. Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. Am J Physiol 2005; 289:H533-41.
9. Currie S, Rainbow RD, Ewart M, et al. IP3R-mediated calcium release is modulated by anandamide in isolated cardiac nuclei. J Mol Cell Cardiol 2008; 45: 801-11.
10. Weis F, Beiras-Fernandez A, Sodian R, et al. Substantially altered expression pattern of cannabinoid receptor 2 and activated endocannabinoid system in patients with severe heart failure. J Mol Cell Cardiol 2010; 48: 1187-93.
11. Banfor PN, Preusser LC, Campbell TJ, et al. Comparative effects of levosimendan, OR-1896, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. Am J Physiol Heart Circ Physiol 2008; 294:H238-48.
12. Polakowski JS, King AJ, Campbell TJ, et al. Cardiovascular effects of Torcetrapib in conscious and pentobarbital-anesthetized dogs. J Cardiovasc Pharmacol 2009; 54: 543-51.
13. 2+ current. Biochem Pharmacol 2010; 80: 1000-6.
14. Yao A, Su Z, Nonaka A, et al. Abnormal myocyte Ca2+ homeostasis in rabbits with pacing-induced heart failure. Am J Physiol Heart Circ Physiol 1998; 274:H1441-8.
15. Varga K, Lake K, Martin BR, Kunos G. Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol 1995; 278: 279-83.
16. Lake KD, Compton DR, Varga K, Martin BR, Kunos G. Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther 1997; 281: 1030-37.
17. Ledent C, Valverde O, Cossu G, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB receptor knockout mice. Science 1999; 283: 401-4.
18. Batkai S, Osei-Hyiaman D, Pan H, et al. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J 2007; 21: 1788-800.
19. Mukhopadhyay P, Rajesh M, Batkai S, et al. CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovasc Res 2010; 85: 773-84.
20. Johnson DE, Heald SL, Dally RD, Janis RA. Isolation, identification and synthesis of an endogenous arachidonic amide that inhibits calcium channel antagonist 1, 4-dihydropyridine binding. Prostaglandings Leukot Essent Fatty Acids 1993; 48: 429-37.
21. Di Marzo V and Fontana A. Anandamide, an endogenous cannabinomimetic eicosanoid: 'killing two birds with one stone'. Prostaglandings Leukot Essent Fatty Acids 1995; 53: 1-11.